Peptide-functionalized, -assembled and -loaded nanoparticles in cancer therapy

Drug Discovery Today, Journal Year: 2024, Volume and Issue: 29(7), P. 103981 - 103981

Published: April 16, 2024

Language: Английский

---

Designing nanozymes for in vivo applications

Nature Reviews Bioengineering, Journal Year: 2024, Volume and Issue: 2(10), P. 849 - 868

Published: July 18, 2024

Language: Английский

---

Cuproptosis‐Driven Enhancement of Thermotherapy by Sequentially Response Cu_2‐xSe via Copper Chemical Transition

Advanced Functional Materials, Journal Year: 2023, Volume and Issue: 33(33)

Published: May 1, 2023

Abstract Activation of cuproptosis pathway has been reported to hold great potential in the application tumor treatment. But efficacy seriously limited by insufficient accumulation sites. Therefore, herein based on strong stabilization effects metalloid element selenium (Se) copper (Cu), a photothermic Cu 2‐ x Se nanoparticle encapsulated with bioresponsive dimethyl maleic anhydride (DMMA@Cu Se) as copper‐carrier improve is constructed, thus achieving cuproptosis‐driven enhancement thermotherapy. This nanosystem exhibits cellular uptake weak acid‐triggered charge‐switching ability. Next step, exposed oxidized and releases divalent high‐level oxide. Then, abundant induces more dihydrolipoamide S ‐acetyltransferase oligomerization down‐regulate FDX1 tricarboxylic acid cycle‐related proteins, which leads inhibiting aerobic respiration. Cuproptosis‐induced mitochondrial damage further improves thermotherapy up‐regulating reactive oxygen species (ROS). In addition, generated ROS also promotes release strengthen cuproptosis, eventually turn. general, DMMA@Cu sequentially triggered copper‐release, efficient appropriate photothermal self‐enhanced nanoplatform for

Language: Английский

---

Different Targeting Ligands-Mediated Drug Delivery Systems for Tumor Therapy

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(2), P. 248 - 248

Published: Feb. 7, 2024

Traditional tumor treatments have the drawback of harming both cells and normal cells, leading to significant systemic toxic side effects. As a result, there is pressing need for targeted drug delivery methods that can specifically target or tissues. Currently, researchers made progress in developing systems therapy using various targeting ligands. This review aims summarize recent advancements therapy, focusing on different ligands such as folic acid, carbohydrates, peptides, aptamers, antibodies. The also discusses advantages, challenges, future prospects these systems.

Language: Английский

---

Biointerface‐Engineered Hybrid Nanovesicles for Targeted Reprogramming of Tumor Microenvironment

Advanced Materials, Journal Year: 2024, Volume and Issue: 36(41)

Published: June 9, 2024

Abstract The tumor microenvironment (TME) of typical types such as triple‐negative breast cancer is featured by hypoxia and immunosuppression with abundant tumor‐associated macrophages (TAMs), which also emerge potential therapeutic targets for antitumor therapy. M1‐like macrophage‐derived exosomes (M1‐Exos) have emerged a promising candidate their tumor‐targeting macrophage‐polarization capabilities. However, the limited drug‐loading efficiency stability M1‐Exos hindered effectiveness in applications. Here, hybrid nanovesicle developed integrating AS1411 aptamer‐conjugated liposomes (AApt‐Lips), termed M1E/AALs. obtained M1E/AALs are loaded perfluorotributylamine (PFTBA) IR780, P‐I, to construct P‐I@M1E/AALs reprogramming TME alleviating engineering TAMs. P‐I@M1E/AAL‐mediated therapy enhances situ generation reactive oxygen species, repolarizes TAMs toward an phenotype, promotes infiltration T lymphocytes. synergistic based on significantly suppresses growth prolongs survival 4T1‐tumor‐bearing mice. By multiple treatment modalities, P‐I@M1E/AAL nanoplatform demonstrates approach overcoming hypoxic immunosuppressive targeted TAM enhanced photodynamic immunotherapy. This study highlights innovative TAM‐engineering platform tumors characterized TME.

Language: Английский

---

Rational Design of Nanozymes for Engineered Cascade Catalytic Cancer Therapy

Chemical Reviews, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 27, 2025

Nanozymes have shown significant potential in cancer catalytic therapy by strategically catalyzing tumor-associated substances and metabolites into toxic reactive oxygen species (ROS) situ, thereby inducing oxidative stress promoting cell death. However, within the complex tumor microenvironment (TME), rational design of nanozymes factors like activity, reaction substrates, TME itself significantly influence efficiency ROS generation. To address these limitations, recent research has focused on exploring that affect activity developing nanozyme-based cascade systems, which can trigger two or more processes tumors, producing therapeutic achieving efficient stable with minimal side effects. This area remarkable progress. Perspective provides a comprehensive overview nanozymes, covering their classification fundamentals. The regulation nanozyme strategies are discussed detail. Furthermore, representative paradigms for successful construction systems treatment summarized focus revealing underlying mechanisms. Finally, we current challenges future prospects development biomedical applications.

Language: Английский

---

Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy

Journal of Controlled Release, Journal Year: 2023, Volume and Issue: 361, P. 270 - 279

Published: Aug. 9, 2023

Language: Английский

---

Peptide nanozymes: An emerging direction for functional enzyme mimics

Bioactive Materials, Journal Year: 2024, Volume and Issue: 42, P. 284 - 298

Published: Sept. 4, 2024

Language: Английский

---

Hyaluronan-decorated copper-doxorubicin-anlotinib nanoconjugate for targeted synergistic chemo/chemodynamic/antiangiogenic tritherapy against hepatocellular carcinoma

Journal of Colloid and Interface Science, Journal Year: 2024, Volume and Issue: 662, P. 857 - 869

Published: Feb. 11, 2024

Language: Английский

---

A Comprehensive Review of Current Approaches in Bladder Cancer Treatment

ACS Pharmacology & Translational Science, Journal Year: 2025, Volume and Issue: 8(2), P. 286 - 307

Published: Jan. 6, 2025

Bladder cancer is one of the most common malignant tumors urinary system globally. It also expensive cancers to manage, due need for extensive treatment and follow-ups that often involve invasive costly procedures. Although there have been some improvements in options, quality life they offer has not improved at same rate as other cancers. Therefore, an urgent find new alternatives ease burden bladder on patients. Recent discoveries opened avenues diagnosis management even though clinical approach largely remained years. The decline cancer-specific mortality regions promote social awareness risk factors reduction carcinogenic exposure demonstrates effectiveness such measures. New agents approved patients who undergone radical cystectomy after Bacillus Calmette-Guérin failure. Current best practices diagnosing treating are presented this review. review discusses radiation therapy, photodynamic gene chemotherapy, nanomedicine relation non muscle-invasive cancers, well systemic treatments.

Language: Английский

---